Luncheon Lectures

Luncheon Lecture 1

Chairperson: Tae Sun PARK (Chonbuk National University, Korea)
Room 1 / 30 August 2019 (Fri)


Which is the better choice to diabetic patients with metabolic syndrom: TZD vs DPP-4 inhibitor
Sung Wan CHUN (Soon Chun Hyang University, Korea)

Luncheon Lecture 2

Chairperson: Sung-Koo KANG (Soon Chun Hyang University, Korea)
Room 2 / 30 August 2019 (Fri)


CaReMe; Putting the pieces of the SGLT-2 inhibitor’s cardio-renal evidence puzzle together
Hye Jin YOO (Korea University, Korea)

Luncheon Lecture 3

Chairperson: Duk Chul LEE (Yonsei University, Korea)
Room 3 / 30 August 2019 (Fri)


Does Lorcaserin have an independent antiglycemic effect beyond weight loss?
Bruce H. FRANCIS (Ben Gurion University, Israel)

Luncheon Lecture 4

Chairperson: Yong Seong KIM (Design Hospital, Korea)
Room 1 / 31 August 2019 (Sat)


A multifactorial approach to obesity treatment with liraglutide 3.0 mg
Yong-ho LEE (Yonsei University, Korea)

Luncheon Lecture 5

Chairperson: Hyunchul LEE (Yonsei Lee Clinic, Korea)
Room 2 / 31 August 2019 (Sat)


SGLT2 inhibitors: hitting the metabolic switch
Merlin C. THOMAS (Monash University, Australia)

Luncheon Lecture 6

Chairperson: Dongsun KIM (Hanyang University, Korea)
Room 3 / 31 August 2019 (Sat)


What’s the benefit of DPPIV inhibitor and TZD Combination in T2DM patients?
Eun-Gyoung HONG (Hallym University, Korea)